Professor Ian Gust is a medical virologist with a distinguished career including the development of vaccines against hepatitis A and human papillomavirus infection. During his 20 years at Fairfield Hospital he built an internationally renowned research team, founded and directed the Burnet Institute, established the National HIV reference laboratory and directed the National Health and Medical Research Council (NHMRC) special unit for AIDS virology. During his subsequent period as R&D Director at CSL Ltd, he laid the basis for the company’s new product portfolio. Ian is the author of 3 books, more than 300 papers and has received several major awards for his work.
Allen Cheng is an infectious diseases physician, Director of Infection Prevention and Healthcare Epidemiology at Alfred Health and Professor of Infectious Diseases Epidemiology at Monash University. He has academic interests in influenza surveillance and vaccination and is Co-chair of the Australian Technical Advisory Group on Immunisation and Chair of the Advisory Committee for Vaccines.
Michel De Wilde
Michel De Wilde holds a PhD in Biochemistry and has a long and successful career in Vaccine Research and Development. He currently consults for the vaccine community.
From 2001 till June 2013, Michel De Wilde was Senior Vice President, Research & Development, at Sanofi Pasteur where he drove the development and licensure of a number of products.
From 1978 till 2000, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility. He played a key role in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine candidate.
Jerome Kim, M.D., is an international expert on the evaluation and development of vaccines and is the Director General of the International Vaccine Institute, whose mission is to discover, develop and deliver safe, effective and affordable vaccines for Global Health. Dr. Kim is also an Adjunct Professor, Department of Medicine, Uniformed Services University and at the Graduate School of Public Health, Yonsei University. He has authored over 300 publications. He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology, and received his M.D. from Yale University School of Medicine.
Wayne C. Koff, Ph.D, is the founding President and CEO of the Human Vaccines Project (HVP), a non-profit global research consortium with the mission to decode the human immune system to accelerate development of vaccines and therapies for infectious and non-communicable diseases. In addition, he is an adjunct professor of epidemiology at the Harvard T.H. Chan School of Public Health (HSPH), where he leads the HSPH-HVP Human Immunomics Initiative, focused on deciphering the principles of effective immunity in aging populations. In 2019, he was honored by Foreign Policy, along with Barack and Michelle Obama and Angela Merkel as one of on the thinkers and doers who had a profound impact on the planet in the last 12 months. Between 1996-2016, Koff led the research and development program for the International AIDS Vaccine Initiative.
Shiranee Sriskandan is Professor of Infectious Diseases and a Clinical Infectious Diseases consultant. She leads the Gram Positive Pathogenesis research group at Imperial College; she is also Clinical Director at the MRC Centre for Molecular Bacteriology and Infection and a Section head.
Her research addresses the mechanisms by which Streptococcus pyogenes causes extreme clinical phenotypes in individuals and populations, examining pathogen molecular microbiology, pathogen transmission, and host immune response, working in collaboration with colleagues in Public Health England. She has a strong interest in streptococcal vaccines and changes in S. pyogenes that might influence vaccine targets.
Mark Sullivan is a development scientist and clinical researcher with a depth of experience in phase I, II and III registrational clinical trials, and has held senior roles in the development of 3 globally approved molecules. Mark was project leader for the registration of moxidectin through the US FDA in 2018 for the treatment of onchocerciasis. He has experience of product development in 6 continents and has also has led vector and DNA-based vaccine development. Mark was 2019 VIC Australian of the Year, EY Australian Entrepreneur 2019 and ATSE Clunies Ross Award winner in 2020. He is an Honorary Professor at UNSW.
Professor Alex Brown (BMed, MPH, PhD, FRACP (hon.), FCSANZ, FAAHMS) is the Aboriginal Health Equity Theme Leader at SAHMRI, and Professor of Medicine at the University of Adelaide. Alex is an internationally leading Aboriginal clinician/researcher who has worked his entire career in Aboriginal health in the provision of public health services, chronic disease care, health care policy and research. He has established three highly regarded research groups over the last 15 years, and much of his work has been at the difficult interface of geographical isolation, complex cultural context, severe socioeconomic disadvantage, inequitable access to and receipt of care and profound health disparities. His transdisciplinary program of research focuses on documenting the burden and contributors to health inequality in Indigenous Australians, with a primary focus on cardiovascular disease (CVD), diabetes and cancer.
Aboriginal and Torres Strait Islander peoples are referred to as Indigenous Australians throughout this website.